Stocks · News reference
Silexion Therapeutics Says Preclinical Study Shows SIL204 Uses Natural Blood Lipids To Enter Cancer Cells, Silence KRAS
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics announced the first patient has been successfully dosed in its Phase 2/3 clinical trial of SIL204, an RNAi therapy for locally advanced pancreatic cancer with KRAS mutations. The trial combines direct intratumoral EUS-guided delivery with subcutaneous dosing alongside standard chemotherapy. The study includes an initial safety cohort of ~18 patients followed by expansion to ~166 patients across Israel and Germany.
Silexion Therapeutics Announces First Patient Dosed Phase 2/3 Clinical Trial Evaluating Lead Candidate, SIL204, In Patients With Locally Advanced Pancreatic Cancer
Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
FingerMotion jumped 18.1% premarket after agreeing to buy Newbit Technology for $2.3M cash; NewGenIvf led gainers at 187.2%, while Silexion fell 16.6%.